EFFECT OF CALCIUM & VITAMIN D ON BONE LOSS FROM HIP--ROLE OF INTERLEUKIN 6

钙的作用

• 批准号: 6264106
• 负责人: Bess Dawson-Hughes
• 金额: $ 4.27万
• 依托单位: TUFTS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264106
• 关键词: binding proteins; bone density; clinical research; diet therapy; dietary calcium; dietary supplements; hip; human data; human old age (65+); human therapy evaluation; human tissue; insulinlike growth factor; interleukin 6; longitudinal human study; nutrition related tag; parathyroid hormones; pathologic bone resorption; sample collection; spine; vitamin D; vitamin therapy

In adults, growth factors and their binding proteins influence bone formation, and the cytokine IL-6 promotes osteoclast recruitment and bone resorption. The primary aims of this proposed supplement to our STOP/IT continuation study are to determine whether supplementation with calcium and vitamin D changes circulating levels of IGF-1, IGFBP-4, and IL-6 and, if so, whether changes in circulating levels of these compounds are associated with the beneficial effect of supplementation on rates of bone loss. This study tests the hypothesis that supplemental calcium and vitamin D, by lowering circulating levels of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D (1,25(OH)2D), will a) decrease the IGFBP-4 medicated inhibition of IGF-1 induced bone formation and b) decrease IL-6 induced bone resorption. At Tufts, 389 adults over age 65 (172 men and 273 women) recently completed a 3-year, randomized, double-blind controlled trial designed to determine whether calcium and vitamin D supplementation reduced rates of bone loss from the total body, hip, and spine. Subjects received either 500mg of calcium plus 700 IU of vitamin D or placebo daily. Bone mineral density and calcium regulating hormone levels and other biochemistries were followed. During the trial, supplementation significantly lowered circulating levels of PTH and 1,25(OH)2D and reduced rates of bone loss from each skeletal site. The proposed study involves assaying archived Tufts STOP/IT samples collected at baseline and after three years of treatment for IGF-1, IGFBP-4, and IL-6. With the addition of these measurements, the STOP/IT data set would offer an enriched opportunity to explore potential mechanisms by which changes in calcium and vitamin D intake influence rates of bone loss.

在成人中，生长因子及其结合蛋白影响骨形成，细胞因子 IL-6 促进破骨细胞募集和骨吸收。 这项对我们的 STOP/IT 继续研究提出的补充的主要目的是确定补充钙和维生素 D 是否会改变 IGF-1、IGFBP-4 和 IL-6 的循环水平，如果是的话，这些化合物的循环水平的变化是否与补充对骨质流失率的有益影响有关。 本研究检验了这样的假设：通过降低甲状旁腺激素 (PTH) 和 1,25-二羟基维生素 D (1,25(OH)2D) 的循环水平，补充钙和维生素 D 将 a) 减少 IGFBP-4 对 IGF-1 诱导的骨形成的药物抑制，b) 减少 IL-6 诱导的骨吸收。 在塔夫茨大学，389 名 65 岁以上的成年人（172 名男性和 273 名女性）最近完成了一项为期 3 年的随机双盲对照试验，旨在确定补充钙和维生素 D 是否可以降低全身、髋部和脊柱的骨质流失率。 受试者每天接受 500 毫克钙加 700 IU 维生素 D 或安慰剂。跟踪骨矿物质密度和钙调节激素水平以及其他生物化学指标。 在试验期间，补充剂显着降低了 PTH 和 1,25(OH)2D 的循环水平，并降低了每个骨骼部位的骨质流失率。 拟议的研究涉及分析在基线和治疗三年后收集的塔夫茨 STOP/IT 存档样本中的 IGF-1、IGFBP-4 和 IL-6。 通过添加这些测量值，STOP/IT 数据集将为探索钙和维生素 D 摄入量变化影响骨质流失率的潜在机制提供丰富的机会。